Articles tagged with: MLN4924
News»
Earlier this year, an international group of myeloma experts published a review of ongoing research into new myeloma treatments. This review not only described a wide range of potential new myeloma treatments, but also included the experts' thoughts on where research into new treatments should go in the future.
Given the recent new drug application for carfilzomib and the upcoming annual meeting of the American Society of Hematology -- which undoubtedly will host discussions of many potential new myeloma treatments -- it seems an appropriate time to go back to the experts' review from …
NewsFlash »
St. Anthony's Triathlon – The Leukemia and Lymphoma Society (LLS) will host the St. Anthony's Triathlon in St. Petersburg, FL on April 26. During the race, participants will swim through Tampa Bay, bike along waterways and harbors, and run through neighborhoods in the area. For more information, visit the LLS Web site.
49th Annual Scientific Meeting Of The British Society For Haematology – The British Society for Haematology will hold its annual conference from April 27 – 29 in Brighton. The conference will include educational sessions, satellite symposiums, and poster sessions. For more information, visit the British Society of Haematology Web site.
MLN4924 Clinical Trials For Multiple Myeloma – Relapsed/refractory multiple myeloma patients are being recruited for a Phase 1 clinical trial involving MLN4924, a drug that inhibits cancer cell proliferation. These Phase 1 clinical trials will test for safety and tolerability as well as disease response. Phase 2 clinical trials involving MLN4924 are expected to begin within the year to test the effectiveness of the drug. MLN4924 is also being tested as a treatment for lymphoma. For more information about the Phase 1 study, visit ClinicalTrials Web site.
2009 Rush Limbaugh Cure-A-Thon For The LLS – To kickoff his 19th annual Cure-A-Thon, which benefits the Leukemia and Lymphoma Society (LLS), Rush Limbaugh personally donated $300,000 toward the search for a cure for blood cancers. In his April 17 broadcast, Limbaugh mentioned that the total number of donors to the Cure-A-Thon increased 33 percent this year, and he is optimistic about raising a record-breaking amount. He praised the efforts of the LLS in education and research, especially noting the society's efforts in supporting the development of Velcade. To read the transcript from his broadcast, visit the Rush Limbaugh show. Donations for the Cure-A-Thon are still being accepted.
For a more detailed listing of myeloma-related events, please check the Myeloma Beacon Events Calendar.